Crystalys Raises $130M for Gout Drug Dotinurad

Crystalys Therapeutics has added $130 million in new financing to push its gout drug dotinurad through pivotal testing, MedCity News reports. Dotinurad is a URAT1 inhibitor, a class designed to help the body clear uric acid, the buildup of which drives the painful inflammation of gout.

Gout is one of the most common inflammatory conditions, yet treatment options remain limited and many patients fail to reach target uric acid levels on existing therapies. That gap is drawing fresh capital and dealmaking. Dotinurad works through the same mechanism as a molecule Sobi brought into its pipeline via a roughly $950 million acquisition, according to MedCity News, underscoring how large pharma is betting on the same target.

For Crystalys, the raise funds the expensive, late-stage trials needed to prove efficacy and safety before any regulatory filing. For the broader field, the money signals that investors see commercial upside in a prevalent, undertreated disease that has long lacked innovation.